Abseamed

Country: Եվրոպական Միություն

language: անգլերեն

source: EMA (European Medicines Agency)

buyitnow

PIL PIL (PIL)
21-08-2023
SPC SPC (SPC)
21-08-2023
PAR PAR (PAR)
03-10-2018

active_ingredient:

epoetin alfa

MAH:

Medice Arzneimittel Pütter GmbH Co. KG

ATC_code:

B03XA01

INN:

epoetin alfa

therapeutic_group:

Antianemic preparations

therapeutic_area:

Anemia; Kidney Failure, Chronic; Cancer

therapeutic_indication:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy).Abseamed can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).Abseamed can be used to reduce exposure to allogeneic blood transfusions in adult non iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml.

leaflet_short:

Revision: 22

authorization_status:

Authorised

authorization_date:

2007-08-27

PIL

                                75
B. PACKAGE LEAFLET
76
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ABSEAMED 1,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 2,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 3,000 IU/0.3 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 4,000 IU/0.4 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 5,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 6,000 IU/0.6 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 7,000 IU/0.7 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 8,000 IU/0.8 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 9,000 IU/0.9 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 10,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 20,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 30,000 IU/0.75 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 40,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
Epoetin alfa
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Abseamed is and what it is used for
2.
What you need to know before you use Abseamed
3.
How to use Abseamed
4.
Possible side effects
5.
How to store Abseamed
6.
Contents of the pack and other information
1.
WHAT ABSEAMED IS AND WHAT IT IS USED FOR
Abseamed contains the active substance epoetin alfa, a protein that
stimulates the bone marrow to
produce more red blood cells which carry haemoglobin (a substance that
transports oxygen). Epoe
                                
                                read_full_document
                                
                            

SPC

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled
syringe
Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled
syringe
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled
syringe
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled
syringe
Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled
syringe
Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 0.5 mL contains 1,000 international units (IU)
corresponding to 8.4 micrograms
epoetin alfa. *
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 1 mL contains 2,000 international units (IU)
corresponding to 16.8 micrograms
epoetin alfa. *
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*
corresponding to 84.0 micrograms per mL
A pre-filled syringe of 0.3 mL contains 3,000 international units (IU)
corresponding
to 25.2 micrograms epoetin alfa. *
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*

                                
                                read_full_document
                                
                            

documents_in_other_languages

PIL PIL բուլղարերեն 21-08-2023
SPC SPC բուլղարերեն 21-08-2023
PAR PAR բուլղարերեն 03-10-2018
PIL PIL իսպաներեն 21-08-2023
SPC SPC իսպաներեն 21-08-2023
PAR PAR իսպաներեն 03-10-2018
PIL PIL չեխերեն 21-08-2023
SPC SPC չեխերեն 21-08-2023
PAR PAR չեխերեն 03-10-2018
PIL PIL դանիերեն 21-08-2023
SPC SPC դանիերեն 21-08-2023
PAR PAR դանիերեն 03-10-2018
PIL PIL գերմաներեն 21-08-2023
SPC SPC գերմաներեն 21-08-2023
PAR PAR գերմաներեն 03-10-2018
PIL PIL էստոներեն 21-08-2023
SPC SPC էստոներեն 21-08-2023
PAR PAR էստոներեն 03-10-2018
PIL PIL հունարեն 21-08-2023
SPC SPC հունարեն 21-08-2023
PAR PAR հունարեն 03-10-2018
PIL PIL ֆրանսերեն 21-08-2023
SPC SPC ֆրանսերեն 21-08-2023
PAR PAR ֆրանսերեն 03-10-2018
PIL PIL իտալերեն 21-08-2023
SPC SPC իտալերեն 21-08-2023
PAR PAR իտալերեն 03-10-2018
PIL PIL լատվիերեն 21-08-2023
SPC SPC լատվիերեն 21-08-2023
PAR PAR լատվիերեն 03-10-2018
PIL PIL լիտվերեն 21-08-2023
SPC SPC լիտվերեն 21-08-2023
PAR PAR լիտվերեն 03-10-2018
PIL PIL հունգարերեն 21-08-2023
SPC SPC հունգարերեն 21-08-2023
PAR PAR հունգարերեն 03-10-2018
PIL PIL մալթերեն 21-08-2023
SPC SPC մալթերեն 21-08-2023
PAR PAR մալթերեն 03-10-2018
PIL PIL հոլանդերեն 21-08-2023
SPC SPC հոլանդերեն 21-08-2023
PAR PAR հոլանդերեն 03-10-2018
PIL PIL լեհերեն 21-08-2023
SPC SPC լեհերեն 21-08-2023
PAR PAR լեհերեն 03-10-2018
PIL PIL պորտուգալերեն 21-08-2023
SPC SPC պորտուգալերեն 21-08-2023
PAR PAR պորտուգալերեն 03-10-2018
PIL PIL ռումիներեն 21-08-2023
SPC SPC ռումիներեն 21-08-2023
PAR PAR ռումիներեն 03-10-2018
PIL PIL սլովակերեն 21-08-2023
SPC SPC սլովակերեն 21-08-2023
PAR PAR սլովակերեն 03-10-2018
PIL PIL սլովեներեն 21-08-2023
SPC SPC սլովեներեն 21-08-2023
PAR PAR սլովեներեն 03-10-2018
PIL PIL ֆիններեն 21-08-2023
SPC SPC ֆիններեն 21-08-2023
PAR PAR ֆիններեն 03-10-2018
PIL PIL շվեդերեն 21-08-2023
SPC SPC շվեդերեն 21-08-2023
PAR PAR շվեդերեն 03-10-2018
PIL PIL Նորվեգերեն 21-08-2023
SPC SPC Նորվեգերեն 21-08-2023
PIL PIL իսլանդերեն 21-08-2023
SPC SPC իսլանդերեն 21-08-2023
PIL PIL խորվաթերեն 21-08-2023
SPC SPC խորվաթերեն 21-08-2023
PAR PAR խորվաթերեն 03-10-2018

view_documents_history